NCR3 and tuberculosis: One clinical trial in Cambodia reported a significantly higher NK cell degranulation capacity in IRIS patients before cART and after 2 weeks of TB treatment than in non-IRIS patients, followed by decreased expression of NK cell activating receptors (NKp30, NKp46, and NKG2D) at IRIS onset (21).